Microbiota

Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, March 21, 2024
Research, U.S. FDA, Conference, Growth, Journey, Agreement, FY, IGA, Microbiota, Risk, New Drug Application, Patient, Food and Drug Administration, Rosacea, Hyperhidrosis, NDA, Red, News, Adjustment, Dermatology, Clinical trial, Erythema, Doxycycline, Safety, GAAP, Food, Marketing, FDA, CEA, Total, PDUFA, Pharmaceutical industry

SCOTTSDALE, Ariz., March 21, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the full year ended December 31, 2023.

Key Points: 
  • ET to discuss the financial results and provide a business update
    SCOTTSDALE, Ariz., March 21, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the full year ended December 31, 2023.
  • Claude Maraoui, Journey Medical’s Co-Founder, President and Chief Executive Officer, said, “2023 was a year of growth and development for Journey Medical.
  • In December 2023, Journey Medical entered into a $20.0 million credit facility with SWK Holdings Corporation (“SWK”), a specialized finance company with a focus on the global healthcare sector.
  • In July 2023, Journey Medical announced positive topline results from the two DFD-29 Phase 3 clinical trials (MVOR-1 & MVOR-2) for the treatment of rosacea.

Global Microbiome Manufacturing Markets 2023-2024 & 2035: Industry Trends, Forecasts, Formulation, Primary Packaging Used, Scale of Operation, Company Size, Key Regions and Leading Developers - ResearchAndMarkets.com

Retrieved on: 
Friday, April 5, 2024
Vitamins, Supplements, Neurology, Fitness & Nutrition, Clinical Trials, Other Health, Biotechnology, Alternative Medicine, General Health, Pharmaceutical, Health, Clostridioides difficile infection, Type, Organization, Database, AOBiome, Microbiota, Patient, CNS, CGMP, Research, Fungus, FDF, Bacteria, Virus, Laboratory, Overalls, Infection, DSM-IV codes, API, Safety, Phase, Therapy, USD, LBP

Likewise, the ecological system of commensal, symbiotic, and pathogenic microorganisms that reside within a host system is called the microbiome.

Key Points: 
  • Likewise, the ecological system of commensal, symbiotic, and pathogenic microorganisms that reside within a host system is called the microbiome.
  • Further, this microbiome manufacturing market analysis highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry.
  • Around 43% of the global microbiome contract manufacturing capacity is installed in facilities owned by small contract manufacturing companies.
  • This market report includes an easily searchable excel database of all the microbiome contract manufacturing companies and their manufacturing facility, worldwide.

MaaT Pharma Strengthens Executive Team Appointing Jonathan Chriqui as Chief Business Officer

Retrieved on: 
Thursday, March 21, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Neurology, Growth, Survival, Doctor of Pharmacy, Microbiota, Maat, Patient, Ipsen, Cancer, MET, Pharmaceutical industry

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, today announced the appointment of Jonathan Chriqui, PharmD, as Chief Business Officer and member of the executive management team.

Key Points: 
  • MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, today announced the appointment of Jonathan Chriqui, PharmD, as Chief Business Officer and member of the executive management team.
  • Jonathan Chriqui will be responsible for MaaT Pharma’s business development and partnering strategies along with promoting MaaT Pharma's innovations within the microbiome industry.
  • MaaT Pharma is now poised to propel its lead asset, MaaT013, into the next phase of development and prepare for its commercial launch,” said Hervé Affagard, Chief Executive Officer and co-founder of MaaT Pharma.
  • I look forward to contributing to the advancement of MaaT013 towards the market and supporting the company’s mission of providing new treatment options for patients with cancer,” shared Jonathan Chriqui, Chief Business Officer at MaaT Pharma.

INTRODUCING BYOMA BODY

Retrieved on: 
Wednesday, March 13, 2024
PHA, TIME, Face, Cell, Hyperpigmentation, Science, Microbiota, Complex, Inflammation, NMF, Dermis, Red, Skin, Ceramide, Love, BLUE, Irritation, BETA, Sphingolipid, Cholesterol, Dicarboxylic acid, Gland, Itch, Cosmetics

NEW YORK, March 13, 2024 /PRNewswire/ -- BYOMA BODY is here to disrupt and democratize the bodycare category in the same way we revolutionized skincare – bringing best-in-class barrier care and skin-compatible science below the neck. This is accessible, affordable, and approachable barrier care for the rest of you – targeted, clinically efficacious, sensorial formulas for your best body.

Key Points: 
  • BYOMA Body is here to change that.
  • Skin does not have a uniform composition, so we are more likely to experience different issues on our body than on our faces.
  • BYOMA has carefully studied the science of skin – breaking down the barrier from the lipid layer to the microbiome.
  • This is a breakthrough in skin science that delivers the same level of care to your body as you show your face.

Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting

Retrieved on: 
Monday, March 11, 2024
American Academy of Dermatology, Microbiota, Marketing, FDA, U.S. FDA, Skin, Forehead, Entrepreneurship, Risk, AAD, Safety, GI, Red, Rosacea, Minocycline, Patient, Clinical trial, Erythema, Vagina, Microbiology, American Academy

SCOTTSDALE, Ariz., March 11, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, announces that data from the Phase 1 clinical trial (DFD-29-CD-006) assessing the impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on the microbial flora of healthy adults were presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting that took place March 8-12, 2024, in San Diego, CA. The clinical trial also assessed the safety and tolerability of the treatment. The data were presented by Srinivas Sidgiddi, M.D., Vice President, Research & Development of Journey Medical. DFD-29 is being developed for the treatment of rosacea in collaboration with Dr. Reddy’s Laboratories Ltd.

Key Points: 
  • The clinical trial also assessed the safety and tolerability of the treatment.
  • The data were presented by Srinivas Sidgiddi, M.D., Vice President, Research & Development of Journey Medical.
  • Microbiological samples were collected from the skin (forehead), stool and vagina at multiple timepoints through the study.
  • Additional information on the DFD-29 Phase 1 clinical trial can be found on ClinicalTrials.gov using the identifier NCT05597462 .

MaaT Pharma Announces Positive Review from the DSMB on the Ongoing Phase 1 Clinical Trial Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)

Retrieved on: 
Thursday, February 29, 2024
Research, Genetics, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, Science, Oncology, Hematopoietic stem cell transplantation, SLA, Microbiota, HSCT, Safety, MET, Bone marrow, Charcot disease, Patient, Clinical trial, Survival, DSMB, Cancer, Pharmaceutical industry

The DSMB recommended that the trial continue without modifications.

Key Points: 
  • The DSMB recommended that the trial continue without modifications.
  • The DSMB, composed of 4 independent experts, including an ALS patient association representative, concluded that safety was good.
  • More precisely, it should be noted that no serious or severe adverse events were observed, and no infectious events could be related to MaaT033.
  • The preliminary results reinforce confidence in the safety of MaaT033, a drug candidate produced by combining the microbiota from multiple donors using a "pooling" process.

Tate & Lyle Partners with Cryptobiotix: New ex-vivo study on low and no calorie sweeteners finds positive impact or no impact on human gut microbiota

Retrieved on: 
Thursday, February 15, 2024
Sorbitol, Erythritol, Stevia, Nutrition, Diet, Research, Molecular biology, Microbiota, Food, Potassium, Food science, Tate & Lyle, Drink, Psicose, Canadian International Council, Soft drink

Tate & Lyle PLC (Tate & Lyle), a world leader in ingredient solutions for healthier food and drink, partnered with Cryptobiotix, pioneers in preclinical gastrointestinal research, on the study.

Key Points: 
  • Tate & Lyle PLC (Tate & Lyle), a world leader in ingredient solutions for healthier food and drink, partnered with Cryptobiotix, pioneers in preclinical gastrointestinal research, on the study.
  • The doses of low and no calorie sweeteners used were based on actual intakes, regulations and amounts that are generally included in foods and beverages during different timepoints.
  • Assessments of additional low and no calorie sweeteners, including allulose and erythritol, are being completed and details will be shared in due course.
  • The low and no calorie sweeteners studied for this paper included: Acesulfame potassium (aceK), maltitol, sorbitol, stevia, sucralose and tagatose.

New ex-vivo study on low and no calorie sweeteners finds positive impact or no impact on human gut microbiota

Retrieved on: 
Thursday, February 8, 2024
Sorbitol, Psicose, Drink, Potassium, Molecular biology, Microbiota, Food science, Nutrition, Tate & Lyle, Stevia, Diet, Food, Research, Canadian International Council, Erythritol, Soft drink

Tate & Lyle and Cryptobiotix's breakthrough ex-vivo* study shows that sucralose does not impact the gut microbiota, while other low and no calorie sweeteners have potentially beneficial health effects

Key Points: 
  • Tate & Lyle and Cryptobiotix's breakthrough ex-vivo* study shows that sucralose does not impact the gut microbiota, while other low and no calorie sweeteners have potentially beneficial health effects
    LONDON, Feb. 8, 2024 /PRNewswire/ - A new, first-of-its-kind study has identified unique and potentially beneficial interactions between certain low and no calorie sweeteners, including stevia, and the human gut microbiota.
  • The doses of low and no calorie sweeteners used were based on actual intakes, regulations and amounts that are generally included in foods and beverages during different timepoints.
  • Assessments of additional low and no calorie sweeteners, including allulose and erythritol, are being completed and details will be shared in due course.
  • The low and no calorie sweeteners studied for this paper included: Acesulfame potassium (aceK), maltitol, sorbitol, stevia, sucralose and tagatose.

Empress Announces Formation of World Leading Scientific Advisory Board

Retrieved on: 
Tuesday, January 23, 2024
Software, Research, General Health, Pharmaceutical, Technology, Artificial Intelligence, Genetics, Health Technology, Science, Biotechnology, Other Science, Health, Probability, Microbiome, Emperor, Harvard Medical School, National academy, Computational biology, Genetic engineering, Inflammatory bowel disease, University, Infection, Biological engineering, Therapy, Synthetic biology, DNA, Harvard University, Biostatistics, Biomedical engineering, MIT, Disease, NIH, Science Publishing Group, MacArthur Fellows Program, Metabolism, Wyss Institute, Entrepreneurship, Artificial intelligence, Cell growth, Distinguishing, Immunology, SAB, Dysbiosis, Microbiota, Biology, Dana–Farber Cancer Institute, Huntsman Cancer Institute, Mass spectrometry, Princeton University, Genomics, Public health, Protein, Diabetes, Pharmaceutical industry

Empress Therapeutics , a company accelerating small molecule drug generation through novel insights linking genes to chemistry, today announced the formation of the Empress Scientific Advisory Board (SAB) with leading experts in synthetic biology, computational biology, genetics, chemistry, and metabolism and disease.

Key Points: 
  • Empress Therapeutics , a company accelerating small molecule drug generation through novel insights linking genes to chemistry, today announced the formation of the Empress Scientific Advisory Board (SAB) with leading experts in synthetic biology, computational biology, genetics, chemistry, and metabolism and disease.
  • The SAB will work closely with the leadership at Empress Therapeutics to advance the company’s Chemilogics™ platform and pipeline of drug leads.
  • “We are honored to have these extraordinary scientific leaders join Empress in its mission to generate safe, effective medicines faster and more predictably,” said Jason Park, Ph.D., Co-Founder and CEO of Empress Therapeutics.
  • “Our Scientific Advisory Board provides invaluable expertise across multiple aspects of our Chemilogics™ platform, which uses AI to discover therapeutic chemistry encoded in genetic data.

The Biocodex Group Strengthens Its Position in Microbiota, With the Signature of a Licensing Agreement With My Health, a Belgian Biotech Company Specializing in Microbiota Solutions

Retrieved on: 
Wednesday, January 17, 2024
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Medical Devices, Vitamins, Supplements, The Lancet, Partnership, Indigestion, Acquisition, Ultra, Probiotic, Microbiota, Trial of the century

Biocodex, a French pharmaceutical group with expertise in microbiota, women's health, orphan diseases, and My Health, a Belgian biotech company specializing in microbiota solutions, announce that they have signed a licensing agreement covering several countries in which the Biocodex Group operates, to market the DUOSPORE® dietary supplement.

Key Points: 
  • Biocodex, a French pharmaceutical group with expertise in microbiota, women's health, orphan diseases, and My Health, a Belgian biotech company specializing in microbiota solutions, announce that they have signed a licensing agreement covering several countries in which the Biocodex Group operates, to market the DUOSPORE® dietary supplement.
  • My Health was founded in 2017 by Raf Dybajlo.
  • In 2021, the company published a clinical study in The Lancet Gastroenterology & Hepatology on the efficacy of My Health’s proprietary strains, MY01 & MY02, in the treatment of functional dyspepsia (unexplained stomach complaints).
  • Raf Dybajlo, CEO of My Health, expresses enthusiasm for the strategic partnership with Biocodex: “I’m honored that My Health’s innovative research and commercial success have been recognized by Biocodex.